Prevention of Side Effects of Intraperitoneal Hyperthermic Perfusion An attempt to reduce scald injury on the peritoneo-serosal surface

• Published in: Nihon Haipāsāmia Gakkai shi Vol. 11; no. 2; pp. 180 - 184
• Main Authors: Kobayashi, Kokuriki, Fujimoto, Shigeru, Takahashi, Makoto, Mutou, Takaaki, Yamano, Hajime
• Format: Journal Article
• Language: English
• Published: Japanese Society for Thermal Medicine 01.06.1995
• Subjects: Cimetidine; Gastric cancer; Hyperthermo-chemotherapy; Peritoneal dissemination
• ISSN: 0911-2529; 1881-9516
• DOI: 10.3191/thermalmedicine.11.180

In the patients who receive intaperitoneal hyperthermo-chemotherapy, scald injury on the normal peritoneo-serosal surface is inevitable due to high temperature in the peritoneal cavity. In an attempt to reduce this scald injury, cimetidine (histamine H2-receptor antagonist) was used for the patients who underwent intraperitoneal hyperthermic perfusion (IPHP), and catheter duodenostomy was placed for these patients in order to decrease postoperative morbidity. IPHP was performed for 60 advanced gastric cancer patients who were allocated to two groups. One was the cimetidine group of 23 patients who received 50 mg/kg of cimetidine intravenously just before IPHP. The other was the control group of 37 patients who did not receive cimetidine. IPHP was performed just after surgery under hypothermic general anesthesia for 90120 minutes. Heated perfusate which contained 10 μg/ml of mitomycin C was circulated in the peritoneal cavity with the inflow and the outflow temperature of 45.546.5°C and 43.544.5°C respectively. The amount of peritoneal exudate and the amount of protein in it of the cimetidine group were significantly smaller than those of the control group after IPHP. There was no anastomotic leakage in the patients who underwent catheter duodenostomy in the cimetidine group. These results suggest that the side effects of IPHP can be reduced by the use of cimetidine and catheter duodenostomy.